NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

This work was guided by a strategic principles working group, with oversight from the NICE Clinical Directorate. In 2023, the working group met with key internal representatives for each area before ...

NICE will routinely identify and contact relevant individuals and organisations at planned points in the topic prioritisation process. This usually occurs at topic identification stage, topic briefing ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

NICE brings a set of unique strengths to the areas of public health, social care and rare diseases. However, guidance on these topics may draw on a wider evidence base, and population benefits and ...

We are introducing a new overarching approach to prioritisation and topic selection, which supports greater integration. This new approach will see the creation of a central and integrated ...

NICE identifies the priorities of the health and care system by engaging with national policy teams, clinical leaders, patient groups, system partners, national innovation awards and commissioners, to ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...